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  A
typical haemolytic uraemic 
syndrome (aHUS) is a rare 
disease involving haemolytic 
anaemia, thrombocytopenia, and renal 
failure. There is growing evidence that 
the disease is associated with defective 
control of the alternative pathway of 
complement [1]. 
    Genetic abnormalities in 
complement regulatory proteins, 
including complement factor H 
(CFH), membrane cofactor protein, 
and complement factor I, have been 
reported in 30%, 10%, and 5% of 
patients with aHUS, respectively [2–4]. 
CFH is a plasma protein produced 
by the liver that acts as a central 
regulator in the alternative pathway 
of complement activation. CFH acts 
as a cofactor for complement factor 
I in the inactivation of the central 
complement protein C3b to form iC3b. 
CFH also accelerates the decay of the 
C3 convertase C3bBb of the alternative 
pathway, and competes with factor B 
for binding to C3b [5]. 
  The   CFH  Gene and CFH Protein
    The gene encoding CFH is situated, 
together with genes for ﬁ  ve factor H-
related proteins (CFHL1–5), within 
the regulator of complement activation 
(RCA) gene cluster at chromosome 
position 1q32 [6,7]. In 1998 a linkage 
was established between the RCA gene 
cluster at 1q32 and the disease [8]. 
In this region there are several large 
genome duplications, also known as 
low copy repeats (LCRs), resulting in 
a high degree of sequence identity 
between   CFH   and the ﬁ  ve   CFHL   genes. 
By sequence analysis a heterozygous 
mutation in   CFH   was found in affected 
patients and obligate carriers within 
one family, providing the ﬁ  rst evidence 
that CFH genetic abnormalities played 
a role in aHUS [8]. 
    The secreted protein product of 
  CFH   consists of 20 repetitive units, 
named short consensus repeats 
(SCRs), each composed of 60 amino 
acids [5]. Around 70   CFH   mutations 
have been reported in patients with 
aHUS (listed in http:⁄⁄www.FH-HUS.
org/, The Factor H-Associated HUS 
Mutation Database). Most of these 
mutations are heterozygous missense 
mutations that cluster in the exons 
encoding SCRs 19 and 20. Functional 
studies on the mutant proteins have 
shown reduced C3b and heparin 
binding [1] that results in impaired 
control of complement activation on 
the endothelial cell surface. These 
mutations include two nucleotide 
changes, c.3572C>T and c.3590T>C, 
that in some patients occur in 
combination. As the exon encoding 
CFH SCR20 differs from the exon 
encoding CFHL1 SCR5 only at the 
c.3572 and c.3590 nucleotides [9], 
the combined mutation makes CFH 
SCR20 identical to CFHL1 SCR5, a 
phenomeon known as gene conversion.
    A New Study Showing a Hybrid 
Complement Gene
    Theoretically, LCRs such as those 
seen in the RCA cluster not only 
predispose to gene conversion events 
but are also associated with genomic 
rearrangements [10], which usually 
result from nonallelic homologous 
recombination (i.e., a recombination 
among different domains and exons 
with high homology that can generate 
new gene structures) between LCRs. 
There is already evidence that a 
nonallelic recombination between 
  CFHL1   and   CFH   that results in 
the deletion of   CFHL1   occurs as a 
common polymorphism in the general 
population. In a new study in   PLoS 
Medicine  , Goodship and colleagues [11] 
tested the intriguing hypothesis that 
a particular nonallelic recombination 
may occur in patients with aHUS that 
leads to the formation of a hybrid   CFH/
CFHL1   gene [11]. 
    To test their hypothesis, the authors 
studied a large pedigree comprising 
eight patients over four generations 
who developed severe forms of aHUS. 
Although linkage analysis had shown 
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evidence of disease segregation with 
the RCA cluster [8], a mutation search 
in two candidate genes,   CFH   and 
  MCP  , within this region failed to show 
evidence of any mutation. Now the 
authors provide strong evidence that 
the affected and obligate carriers within 
this family carry a heterozygous hybrid 
gene that derived from a crossing-over 
between intron 21 of   CFH   and intron 
4 of   CFHL1  . The hybrid gene consists 
of the ﬁ  rst 21 exons of   CFH   (encoding 
SCRs 1–18 of CFH) and the last two 
exons of   CFHL1   (encoding SCR4 and 
5 of CFHL1). The protein product 
of the hybrid gene is identical to the 
CFH mutant protein S1191L/V1197A, 
which arises by gene conversion 
(i.e., the aforementioned c.3572C>T 
and c.3590T>C) and lacks surface 
complement regulatory activity.
    These results provide a new 
mechanism leading to CFH 
abnormalities in aHUS and show the 
complexity of genetic screening of 
  CFH   family genes. Since the hybrid 
gene cannot be picked up by genomic 
screening, which uses   CFH  -speciﬁ  c 
primers, theoretically some patients 
that apparently have normal results 
on   CFH   screening may instead carry a 
hybrid gene. Based on this hypothesis 
the authors suggest [11] performing 
  CFH   screening by multiplex ligation-
dependent probe ampliﬁ  cation in all 
patients with aHUS. Their position is 
strengthened by ﬁ  nding the hybrid 
gene in three additional unrelated 
patients with aHUS, indicating that the 
abnormality is not restricted to a single 
pedigree. However, larger studies in 
other independent patient cohorts 
should be performed to establish the 
frequency of such an abnormality 
within the aHUS population.
  Clinical  Implications
    Identiﬁ  cation of the speciﬁ  c genetic 
defect in patients with aHUS could 
enhance diagnostic precision, predict 
clinical outcomes, and, hopefully, 
translate into improved management 
of the disease. As CFH is a plasma 
protein produced mainly by the liver, 
kidney transplantation in patients 
with aHUS with   CFH   mutations who 
have progressed to end-stage renal 
disease is associated with 80% of graft 
loss due to disease recurrence [12]. 
Patients with aHUS should therefore 
be screened for any possible   CFH   
abnormality before inclusion on a 
transplant list to avoid exposing the 
patient to an unacceptable risk of 
disease recurrence. On the other hand, 
patients with   CFH   abnormalities will 
beneﬁ  t from ongoing efforts to obtain 
speciﬁ  c replacement therapies with 
plasma fractions enriched in CFH.
  Next  Steps
    Nowadays, screening for gene mutations 
is being performed at several clinical 
and research centres in industrialized 
countries. However multiplex ligation-
dependent probe ampliﬁ  cation, which 
is required to identify the hybrid gene, 
is a very specialized procedure and few 
centres may be equipped to perform 
it. Thus further work is needed to 
identify and validate an easier test to 
reliably identify the   CFH/CFHL   hybrid 
gene. Whether other recombination 
events could occur in aHUS, generating 
different   CFH/CFHL   hybrid genes, 
should also be investigated.   
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